Skip to main content

Table 3 Baseline information of NSCLC patients with EGFR mutation

From: Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology

Clinical factors Patients (%) Death Log-rank test, p
Age
  > =65 24 (53.3%) 14 0.70
  < 65 21 (46.7%) 9  
Gender
 Male 13 (28.9%) 7 0.6
 Female 32 (71.1%) 16  
Race
 Asian 2 (4.4%) 1 0.6
 Black or African American 3 (6.7%) 1  
 Not reported 4 (8.9%) 1  
 White 36 (80.0%) 20  
Cancer Status
 Tumor free 20 (44.4%) 6 0.01*
 With tumor 15 (33.3%) 12  
 Unknow 10 (22.2) 5  
Stage
 Stage I 22 (48.9%) 9 0.6
 Stage II 9 (20.0%) 5  
 Stage III 11 (24.4%) 8  
 Stage IV 2 (4.4%) 1  
 Not reported 1 (2.2%) 0